Unity Biotechnology Inc.
SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX]UNITY, a biotechnology company developing therapeutics to slow, halt or reverse the progression of aging-related diseases, today announced that the Compensation Committee of its Board of Directors (the “Board”) has granted stock-based awards effective July 22, 2024 covering an aggregate of 115,000 shares of UNITY common stock to its new employee, its Chief Strategy Officer, including options to purchase an aggregate of 100,000 shares of UNITY common stock and 15,000 restricted stock units of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Attractiveness Incentive Plan, as amended, which was approved by the Board of Directors in March 2020 for the purpose of providing grants to new employees as a material inducement to commence employment with UNITY, pursuant to Nasdaq Stock Market Rule 5635(c)(4).
About UNITY
UNITY is developing a new class of therapeutics to slow, stop or reverse the progression of age-related diseases. UNITY is currently focused on developing medicines to selectively remove or modulate senescent cells, thereby providing breakthrough treatments for age-related eye and neurological diseases. For more information, visit www.unitybiotechnology.com or follow us on X and LinkedIn.
Media Contact
Inizio Evoke Communications
Katherine Smith
Katherine.Smith@inizioevoke.com
Investor Contacts
LifeSciAdvisors LLC
Joyce Allaire
jallaire@lifesciadvisors.com
